Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Nutr Sci Vitaminol (Tokyo) ; 59(5): 454-61, 2013.
Article in English | MEDLINE | ID: mdl-24418880

ABSTRACT

Since the discovery that hepcidin is expressed in the adipose tissue of obese subjects, attention has been increasingly focused on alterations in iron homeostasis that are associated with adiposity. We examined the production of hepcidin, the expression of hepcidin-related genes and the iron content of the adipose tissue in obesity using Swiss mice fed a high-fat diet (HFD). The mice were maintained on a control diet or HFD for 12 or 24 wk, and body weight, adiposity and glucose homeostasis were evaluated. The expression of several genes (hepcidin, TfR1, TfR2, DMT1, FT-heavy, ferroportin, IRP-1, IRP-2 and HIF-1) and the protein expression of hepcidin and IL-6 were quantified. The iron level was assessed using a Prussian blue reaction in paraffin-embedded tissue. After 24 wk on the HFD, we observed increases in the levels of hepcidin in the serum and the visceral adipose tissue. The IL-6 levels also increased in the visceral adipose tissue. Adipocytes isolated from the visceral adipose tissues of lean and obese mice expressed hepcidin at comparable levels; however, isolated macrophages from the stromal vascular fraction expressed higher hepcidin levels. Adipose tissues from obese mice displayed increased tfR2 expression and the presence of iron. Our results indicate that IL-6 and iron may affect the signaling pathways governing hepcidin expression. Thus, the mice fed HFD for 24 wk represent a suitable model for the study of obesity-linked hepcidin alterations. In addition, hepcidin may play local roles in controlling iron availability and interfering with inflammation in adipose tissue.


Subject(s)
Adiposity , Hepcidins/metabolism , Intra-Abdominal Fat/metabolism , Macrophages/immunology , Obesity/metabolism , Subcutaneous Fat/metabolism , Up-Regulation , Animals , Cells, Cultured , Diet, High-Fat/adverse effects , Down-Regulation , Gene Expression Regulation , Hepcidins/blood , Hepcidins/genetics , Interleukin-6/blood , Interleukin-6/metabolism , Intra-Abdominal Fat/immunology , Intra-Abdominal Fat/pathology , Iron/blood , Iron/metabolism , Liver/immunology , Liver/metabolism , Liver/pathology , Macrophages/metabolism , Macrophages/pathology , Male , Mice , Obesity/etiology , Obesity/immunology , Obesity/pathology , Random Allocation , Receptors, Transferrin/genetics , Receptors, Transferrin/metabolism , Signal Transduction , Specific Pathogen-Free Organisms , Subcutaneous Fat/immunology , Subcutaneous Fat/pathology , Weight Gain
2.
Scand J Gastroenterol ; 47(8-9): 943-50, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22630819

ABSTRACT

OBJECTIVE: Infliximab is a monoclonal anti-TNF-α antibody that is used therapeutically to treat Crohn's disease (CD). High levels of pro-inflammatory cytokines, especially TNF-α, have been observed in the gastrointestinal tract of CD patients and were associated with alterations in the mesenteric adipose tissue, which also contributed to the high levels of adipokine release. The authors used a rat model of colitis that produces mesenteric adipose tissue alterations that are associated with intestinal inflammation to study the effects that infliximab treatment has on adipokine production, morphological alterations in adipose tissue and intestinal inflammation. MATERIAL AND METHODS: The ability of infliximab to neutralize rat TNF-α was evaluated in vitro using U937 cells. Colitis was induced by repeated intracolonic trinitrobenzene sulfonic acid instillations and was evaluated by macroscopic score, histopathological analysis, myeloperoxidase activity, TNF-α and IL-10 expression as well as iNOS (inducible NO synthase) expression and JNK phosphorylation in colon samples. The alterations in adipose tissue were assessed by TNF-α, IL-10, leptin, adiponectin and resistin levels as well as adipocyte size and peroxisome proliferator-activated receptor (PPAR)-γ expression. RESULTS: Infliximab treatment controlled intestinal inflammation, which reduced lesions and neutrophil infiltration. Inflammatory markers, such as iNOS expression and JNK phosphorylation, were also reduced. In mesenteric adipose tissue, infliximab increased the production of IL-10 and resistin, which was associated with the restoration of adipocyte morphology and PPAR-γ expression. CONCLUSIONS: Our results suggest that infliximab could contribute to the control of intestinal inflammation by modifying adipokine production by mesenteric adipose tissue.


Subject(s)
Adipose Tissue/drug effects , Adipose Tissue/metabolism , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Antibodies, Monoclonal/pharmacology , Colitis/metabolism , Colitis/pathology , Adipose Tissue/pathology , Analysis of Variance , Animals , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Antibodies, Monoclonal/therapeutic use , Cell Survival/drug effects , Colitis/chemically induced , Colitis/drug therapy , Disease Models, Animal , Gene Expression , Humans , Infliximab , Interleukin-10/metabolism , JNK Mitogen-Activated Protein Kinases/drug effects , JNK Mitogen-Activated Protein Kinases/metabolism , Male , Mesentery , Nitric Oxide Synthase Type II/drug effects , Nitric Oxide Synthase Type II/metabolism , PPAR gamma/drug effects , PPAR gamma/genetics , PPAR gamma/metabolism , Peroxidase/metabolism , Phosphorylation , RNA, Messenger/metabolism , Rats , Rats, Wistar , Resistin/metabolism , Trinitrobenzenesulfonic Acid , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/metabolism , Tumor Necrosis Factor-alpha/pharmacology , U937 Cells
SELECTION OF CITATIONS
SEARCH DETAIL
...